Profile data is unavailable for this security.
About the company
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.
- Revenue in USD (TTM)60.11bn
- Net income in USD365.00m
- Incorporated1970
- Employees72.00k
- LocationMerck & Co Inc2000 Galloping Hill RoadKENILWORTH 07033United StatesUSA
- Phone+1 (908) 740-4000
- Fax+1 (908) 423-1987
- Websitehttps://www.merck.com/
Mergers & acquisitions
Acquired company | MRK:NYQ since announced | Transaction value |
---|---|---|
Caraway Therapeutics Inc | 28.51% | 610.00m |
Prometheus Biosciences Inc | 14.43% | 10.93bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie Inc | 54.32bn | 4.82bn | 322.43bn | 50.00k | 66.96 | 31.04 | 23.71 | 5.94 | 2.72 | 2.72 | 30.63 | 5.87 | 0.3972 | 4.75 | 4.85 | 1,086,360.00 | 3.56 | 6.55 | 4.73 | 8.40 | 66.45 | 69.74 | 8.97 | 16.46 | 0.7638 | 9.12 | 0.851 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
Merck & Co Inc | 60.11bn | 365.00m | 334.18bn | 72.00k | 1,011.81 | 8.89 | 78.65 | 5.56 | 0.1304 | 0.1304 | 23.74 | 14.84 | 0.557 | 2.59 | 6.07 | 834,916.70 | 0.3493 | 7.70 | 0.4548 | 10.29 | 73.53 | 72.26 | 0.6271 | 15.03 | 1.00 | 7.61 | 0.4823 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
Johnson & Johnson | 85.16bn | 13.33bn | 381.20bn | 131.90k | 29.93 | 5.54 | 18.66 | 4.48 | 5.29 | 13.84 | 33.52 | 28.57 | 0.4799 | 2.22 | 5.49 | 645,633.10 | 7.51 | 8.93 | 10.54 | 11.96 | 69.18 | 68.17 | 15.65 | 18.86 | 0.9143 | 215.17 | 0.299 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 233.58m | 9.22% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 128.15m | 5.06% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 116.87m | 4.61% |
Wellington Management Co. LLPas of 31 Dec 2023 | 85.60m | 3.38% |
Geode Capital Management LLCas of 31 Dec 2023 | 55.43m | 2.19% |
Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 36.68m | 1.45% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 36.55m | 1.44% |
Norges Bank Investment Managementas of 31 Dec 2023 | 28.51m | 1.13% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 26.66m | 1.05% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 26.17m | 1.03% |